A 2024 global report on national policy, programmes, and progress towards hepatitis B elimination: findings from 33 hepatitis elimination profiles

IF 30.9 1区医学 Q1 GASTROENTEROLOGY & HEPATOLOGY

Lancet Gastroenterology & Hepatology Pub Date : 2025-05-20 DOI:10.1016/s2468-1253(25)00069-x

Lindsey Hiebert-Suwondo, Jana Manning, Rania A Tohme, Maria Buti, Loreta A Kondili, C Wendy Spearman, Nishi Prabdial-Sing, Victoria Turnier, Jeffrey V Lazarus, Imam Waked, John W Ward

{"title":"A 2024 global report on national policy, programmes, and progress towards hepatitis B elimination: findings from 33 hepatitis elimination profiles","authors":"Lindsey Hiebert-Suwondo, Jana Manning, Rania A Tohme, Maria Buti, Loreta A Kondili, C Wendy Spearman, Nishi Prabdial-Sing, Victoria Turnier, Jeffrey V Lazarus, Imam Waked, John W Ward","doi":"10.1016/s2468-1253(25)00069-x","DOIUrl":null,"url":null,"abstract":"The Coaltion for Global Hepatitis Elimination's National Hepatitis Elimination Profiles assess the status of national data, policy, and programme development the elimination of viral hepatitis. Profiles from 33 countries and territories show progress, towards elimination of hepatitis B with 24 (73%) of them meeting the 2025 WHO interim target of 0·5% or less HBsAg prevalence in children younger than 5 years. 22 (67%) of countries and territories profiled have policies for universal hepatitis B birth-dose vaccination of newborns. Access to hepatitis B testing and treatment, including removing HBsAg screening and hepatitis B treatment patient co-payments and simplifying treatment algorithms, remains suboptimal, especially in low-income and middle-income countries and territories. Of the seven profiled countries and territories meeting the 60% WHO 2025 diagnosis coverage target, all but one (Rwanda) is a high-income country or territory. No country or territory has met the WHO 2025 treatment target of at least 50% of people living with hepatitis B receiving treatment. The profiles guide national planning and identify priorities for resource mobilisation to further accelerate hepatitis B elimination.","PeriodicalId":56028,"journal":{"name":"Lancet Gastroenterology & Hepatology","volume":"40 1","pages":""},"PeriodicalIF":30.9000,"publicationDate":"2025-05-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Lancet Gastroenterology & Hepatology","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1016/s2468-1253(25)00069-x","RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"GASTROENTEROLOGY & HEPATOLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

The Coaltion for Global Hepatitis Elimination's National Hepatitis Elimination Profiles assess the status of national data, policy, and programme development the elimination of viral hepatitis. Profiles from 33 countries and territories show progress, towards elimination of hepatitis B with 24 (73%) of them meeting the 2025 WHO interim target of 0·5% or less HBsAg prevalence in children younger than 5 years. 22 (67%) of countries and territories profiled have policies for universal hepatitis B birth-dose vaccination of newborns. Access to hepatitis B testing and treatment, including removing HBsAg screening and hepatitis B treatment patient co-payments and simplifying treatment algorithms, remains suboptimal, especially in low-income and middle-income countries and territories. Of the seven profiled countries and territories meeting the 60% WHO 2025 diagnosis coverage target, all but one (Rwanda) is a high-income country or territory. No country or territory has met the WHO 2025 treatment target of at least 50% of people living with hepatitis B receiving treatment. The profiles guide national planning and identify priorities for resource mobilisation to further accelerate hepatitis B elimination.

查看原文本刊更多论文

关于消除乙型肝炎的国家政策、规划和进展的2024年全球报告：来自33个消除肝炎概况的发现

全球消除肝炎联盟的国家消除肝炎概况评估消除病毒性肝炎方面的国家数据、政策和规划发展状况。来自33个国家和地区的概况显示，在消除乙型肝炎方面取得了进展，其中24个国家（73%）实现了世卫组织2025年5岁以下儿童HBsAg患病率不超过0.5%的中期目标。22个（67%）国家和领土制定了新生儿普遍接种出生剂量乙肝疫苗的政策。获得乙型肝炎检测和治疗，包括取消乙肝表面抗原筛查和乙型肝炎治疗患者共付费用以及简化治疗算法，仍然不够理想，特别是在低收入和中等收入国家和地区。在实现世卫组织2025年60%诊断覆盖率目标的七个国家和领土中，除一个国家（卢旺达）外，其余都是高收入国家或领土。没有任何国家或地区实现世卫组织2025年的治疗目标，即至少50%的乙型肝炎患者接受治疗。这些概况为国家规划提供指导，并确定资源调动的优先事项，以进一步加速消除乙型肝炎。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Lancet Gastroenterology & Hepatology Medicine-Hepatology

CiteScore

50.30

自引率

1.10%

发文量

期刊介绍： The Lancet Gastroenterology & Hepatology is an authoritative forum for key opinion leaders across medicine, government, and health systems to influence clinical practice, explore global policy, and inform constructive, positive change worldwide. The Lancet Gastroenterology & Hepatology publishes papers that reflect the rich variety of ongoing clinical research in these fields, especially in the areas of inflammatory bowel diseases, NAFLD and NASH, functional gastrointestinal disorders, digestive cancers, and viral hepatitis.